

On behalf of the Chief Investigators, Professor Simon Gollins and Dr Ane Appelt and the CTRU Team, welcome to the 8<sup>th</sup> APHRODITE trial newsletter!

Site	Site Code	Total Patients Recruited
St James's	C00050	0
Royal Preston	C00160	0
North Tees	C00256	0
Weston Park	C00354	1
Churchill	C00153	2
Lincoln	C00089	2
Clatterbridge	C00019	2
Christie	C00018	3
Glan Clwyd	C00353	10

### Recruitment

The trial has recruited **20** patients so far as of May 2022. Our ultimate target is to recruit 104 patients into the APHRODITE trial from across the 12 sites selected.

Congratulations to Churchill for recruiting their first 2 patients in March. The table to the left lists the total number of patients recruited per site.

### Site Setup

We continue to support setup at sites opening to the trial. If sites have any queries or are having any difficulties with site set-up, please feel free contact us via the APHRODITE trial inbox.

### Discrete Choice Experiment (DCE)

The APHRODITE patient preference project will enhance and complement the trial results by measuring what aspects of non-surgical management of colorectal cancer are most important to patients. We have recruited **19** participants so far, and **4** participants have already completed the 6-month follow-up survey.

The patient preference project is simple and easy to set up, and we are still interested in opening new sites. If you're not already recruiting for the APHRODITE patient preference project and would like to hear more, please contact [patientpreferenceAPHRODITE@leeds.ac.uk](mailto:patientpreferenceAPHRODITE@leeds.ac.uk)

### New Substantial Amendment

A new substantial amendment has been submitted for REC review, and will be communicated to all sites very soon.

The most important changes include:

- The description of patient population updated - we now emphasise that the trial is open for all patients who express a strong preference for organ preservation
- Updates to patient eligibility criteria to include:
  - Patients with positive lymph nodes in the mesorectum (N1a-b)
  - Tumours up to 5cm in diameter
- Addition of a central review process for baseline MRI, where the scans for the first 2 patients from each site will be reviewed centrally in real-time prior to randomisation

In addition, Addenbrooke's and Southampton have been added as new recruiting sites, and the new YCR logo has been incorporated throughout all documentation

### MACRO Access & Microsoft Edge Update

If you are currently accessing MACRO using Internet Explorer to perform remote data entry, it is advisable to switch to using Microsoft Edge as soon as possible. Microsoft will stop supporting using Internet Explorer to access MACRO for data entry in June this year.

Please note, Microsoft Edge should be available on any computer that currently runs Internet Explorer so this change should not cause any issues with performing remote data entry. If you are having any issues with access, please email the APHRODITE inbox.

If you have any questions or queries about trial setup, please contact Matthew our Trial Management Assistant by emailing the APHRODITE trial inbox at [APHRODITE@leeds.ac.uk](mailto:APHRODITE@leeds.ac.uk)



If you would like your site to be featured on the newsletter then please let us know about your experience of recruiting into the APHRODITE trial!